"Our presentations to the dementia research community at AAIC of this robust set of clinical trial data will allow us to engage directly with scientists and neurologists on in-depth analyses of our findings," said Alfred Sandrock, Jr., M.D., Ph.D., Head of Research and Development at Biogen. Ltd. +781 464 2442 Investor Relations Department IR@biogen.com TEL: : +81-(0)3-3817 . 5 Biogen's response to COVID-19 • Implementing policies and practices to safeguard our employees and communities • Providing medical equipment and supplies and donating 3D-printed personal protective equipment • Committing $10 million from the Biogen Foundation to support global response efforts • Facilitating volunteer efforts by employees • Engaging with investigators who may . Following the webcasts, archived versions will be available on the website. Jun 11, 2021. theInvestorssection of Biogen.com. Why Biogen's Alzheimer's Drug Presentation Left Investors ... Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.com concurrent with the presentation times indicated above. Biogen and Eisai Announce Design of ADUHELM ICARE AD-US ... We disclaim any obligation to supplement or update the information in these presentations or webcasts. Biogen stuns with planned US FDA filing for previously ... Biogen Investor R&D Day. SG, sacituzumab govitecan 4. Kasimov covers . Name *. Motor symptoms of the disease can include slow movement, rigidity, tremors, and impaired balance, while non-motor symptoms can include cognitive impairment, mood or sleep disorders. 1.6 MB. Following the webcasts, archived versions will be available on the website. Biogen Inc.: Biogen and Eisai Announce ADUHELM ... Biogen Inc.: Biogen Announces Late Breakers and Additional ... IR@biogen.com For investor inquiries related to the Nightstar Therapeutics acquisition, please contact Biogen Investor Relations at IR@biogen.com. Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.com concurrent with the presentation times . Corporate Profile. Assessed by independent central review in the brain metastases-negative population 2. Sage Therapeutics and Biogen Announce Positive, One-Year ... - Biogen (Nasdaq: BIIB) today announced it will host webcasts of its pre-recorded presentations and live discussions related to its Alzheimer's disease investigational therapy, aducanumab, at the upcoming AD/PDTM 2021 Virtual Conference. Contact Us - Biogen Biogen : 2021 Investor R&D Day | MarketScreener Events & Presentations | Agenus Inc. - Investors Projects are more in-depth than internship projects and are closely aligned to a student's academic program and . OS, overall survival 3. Corporate Presentations. Pacific Biosciences. Southwest Airlines Co. (NYSE: LUV) invites you to listen to a live webcast of its 2021 Investor Day. The webcast will be live on Monday, January 10, 2022, at 9:45 a.m. During our 2021 R&D Day, we featured presentations on our diversified portfolio across disease areas and therapeutic modalities, which will guide our path forward in . Category. Biogen (BIIB) J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Biogen yesterday and set a price target of $276.00. The Cambridge, Mass.-based company's stock was trading up approximately 36.9% to $305.88 as of 9:45 a.m. * Indicates required fields. Affiliation (Please select one option:) *. Events. Nov. 17, 2021 Investor Day Presentation 10.5 MB Q3 2021 Agios Pharmaceuticals Inc Earnings Conference Call Nov 3, 2021 at 8:00 AM EDT Read More. The information contained in prior presentation materials and webcasts should be considered accurate only as of the date of the presentation or webcast. Southwest will be webcasting the presentation live, and a link to the webcast will be made . Investors eagerly awaited Biogen's (NASDAQ:BIIB) presentation on its investigative Alzheimer's drug at Thursday's Clinical Trials on Alzheimer's Disease conference. Eli Lilly ( LLY) offered two presentations centered on its experimental Alzheimer's drug, donanemab. Investor Relations. Cambridge, Mass. SAGE INVESTOR: Helen Rubinstein (315) 382-3979 Helen.Rubinstein@sagerx.com. Following the webcasts, archived versions will be available on the website. We disclaim any obligation to supplement or update the information in these presentations or webcasts. Biogen recently slashed Aduhelm's price to ,000 a year from . April 10, 2021 at 10:30 AM EDT. BIOGEN MEDIA CONTACT: Ashleigh Koss Tel: +1 908-205-2572 public.affairs@biogen.com. Visit our Investors page for financial information, reporting and news releases Sign up for alerts Both presentations will be available via webcast on the Investor Relations section of www.biogenidec.com. Confident in our sales growth outlook ~ CAGR 4% to 2025 9M 2018 32.4 9M 2019 9M 2020 37.1 9M 2021 34.3 36 . Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen&CloseCurlyQuote;s website at investors.biogen.com concurrent with the presentation times indicated above. One compared the cost-effectiveness of donanemab against Biogen's approved drug, Aduhelm. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. The company's shares closed last Monday at $236.96, close to its 52-week low of $221.72. BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's Early Development Pipeline and Research. BIOGEN INVESTOR: Mike Hencke +1 781 464 2442 IR@biogen.com Biogen investors may have believed after Aduhelm was approved that the company's share price would climb >$400 as a minimum, and indeed it did, but . To access the live webcast, please visit Biogen's Investors section at. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S . . Stocks. Supplemental information in the form of a slide presentation will also be accessible on the internet at the same location at the time of each presentation and will remain on the Biogen Idec website until at least September 30, 2007. Conclusion. AD/PD Webcast Schedule Details: Wednesday, March 10, 2021, 6:45 a.m. April 14, 2021 • Investor Relations CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer's disease investigational therapy, aducanumab, at the upcoming 2021 virtual American Academy of Neurology (AAN) Annual Meeting. The Investor Relations website contains information about Sage Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. ET - Pre-recorded presentation: Cerebrospinal Fluid Biomarker . Scientific Presentations. Source: Q321 results presentation. TPC, treatment of physician's choice. Biogen Digital Health aspires to transform patients' lives and Biogen by making personalized & digital medicine in neuroscience a reality. Non- cambridge, mass., nov. 03, 2021 (globe newswire) -- biogen inc. (nasdaq: biib) announced the company will present a variety of new data from its alzheimer's disease product portfolio and clinical. The information contained in prior presentation materials and webcasts should be considered accurate only as of the date of the presentation or webcast. It does not constitute a prospectus or prospectus equivalent document. The presentation video and slides are available on the investors' section of the Eisai Co., Ltd. website. Scientific Presentations. Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.com concurrent with the presentation times. Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting News A Letter from Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It's Time for Companies to Act Like the Climate Crisis is a Health Crisis Biogen. Email Address *. Download Presentation. Menlo Park, CA 94025. Upcoming Events. The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck Shanthi Rexaline 6/7/2021 Former R. Kelly assistant speaks of 'the look in his . 3d. They were hoping for clues . Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. About ADUHELM™ (aducanumab-avwa) injection 100 mg/mL solution ADUHELM is indicated for the . Investor Contact. CAMBRIDGE, Mass., April 14, 2021-- Biogen today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer' s disease investigational therapy, aducanumab, at . Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.comconcurrent with the presentation times . About ADUHELM ® (aducanumab-avwa) injection 100 mg/mL solution Biogen : 2021 Investor R&D Day. Webelieve that these and other Non-GAAP financial measures provide additional insight into the ongoing economics of BIOGEN INVESTOR CONTACT: Mike Hencke +1 781 464 2442 IR@biogen.com. Read More » PacBio to Acquire Omniome. BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's ALPINE study, EHA 2021 Presentations, and Provide an Update on Brukinsa . Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference. Aug 25, 2021. BIOGEN MEDIA CONTACT: Ashleigh Koss Tel: +1 908-205-2572 public.affairs@biogen.com. Non-GAAP financial measures can be found on slides 41-44 of this presentation and in the Q2 2021 earnings release and related financial tables posted on the Investors section of Biogen.com. At Biogen, our mission is clear: we are pioneers in neuroscience. 2 Important Information For Investors And Stockholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. public.affairs@biogen.com Investor Contact: Biogen Inc. Mike Hencke +781 464 2442 Biogen will also post the presentation on the investors section of its website at investors.biogen.com. Discuss the Biotech industry here. Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. Download. SAGE INVESTOR CONTACT: Helen Rubinstein (315) 382-3979 Helen.Rubinstein@sagerx.com. INVESTOR PRESENTATION MARCH 19, 2019 . biogen media contact: biogen investor contact: Allison Parks Mike Hencke +1 (781) 464-3260 +1 (781) 464-2442 . About ADUHELM® (aducanumab-avwa) injection 100 mg/mL solution Stifel 2021 Virtual Healthcare Conference. Biogen and Eisai receive FDA accelerated . Since our founding in 1978 as one of the world's first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases. - August 27, 2020 - Biogen (Nasdaq: BIIB) today announced it will host a prerecorded webcast of its encore presentation related to its Alzheimer's disease investigational therapy, aducanumab, at the upcoming 61st Annual Meeting of the Japanese Society of Neurology. About ADUHELM® (aducanumab-avwa) injection 100 mg/mL solution Webcast Hosted by William Blair on AGEN1181 and Balstilimab AACR Presentations. Source: Sage Therapeutics, Inc. BIOGEN INVESTOR CONTACT . Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting News A Letter from Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It's Time for Companies to Act Like the Climate Crisis is a Health Crisis Following the webcasts, archived versions will be available on the website. • is a foundational therapy offering immediate transformational benefits in 3L+ mTNBC Stifel 2021 Virtual Healthcare Conference 805.9 KB. According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 18.5% and a 55.4% success rate. Additional ADUHELM Poster Presentations Biogen will present two additional virtual posters about ADUHELM. MEDIA CONTACT: David Caouette +1 617 679 4945 public.affairs@biogen.com: INVESTOR CONTACT: Mike Hencke +1 781 464 2442 IR@biogen.com "The result of the futility analysis was incorrect," Biogen said in its data update presentation. Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference. Read More. Investor R . ET on Oct. 22. 5 Investor Relations │ Q3 2021 Results Company overview Consistent long-term performance driving confidence for the future 5 Novartis Q3 Results | October 26, 2021 | Novartis Investor Presentation Consistent strong performance since 2018. Biogen is valued at a combined total of $34.67 billion by Refinitiv data, and with Samsung looking to drop over six times what Biogen is worth on expansion projects, that likely would have meant at least some premium to get Biogen in the fold. LATE-BREAKING AAIC PRESENTATION EXPLORES POTENTIAL CLINICAL EFFECTS OF LECANEMAB (BAN2401) Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer's Association International Conference (AAIC) To access the live webcast, please visit Biogen's Investors section at. Q1 2021 Biogen Earnings Presentation Apr 22, 2021 Q4 and Full Year 2020 Biogen Earnings Presentation Feb 03, 2021 Q3 2020 Biogen Earnings Presentation Oct 21, 2020 Investor R&D Day 2021 Biogen 2021 Investor R&D Day Sep 21, 2021 Biogen Digital Health Sep 21, 2021 Advancements in Research Sep 21, 2021 Alzheimer's Disease Research Portfolio BIOGEN MEDIA: Ashleigh Koss Tel: +1 908-205-2572 public.affairs@biogen.com. August 27, 2020 • Investor Relations Cambridge, Mass. Company Overview. Buy side Sell side Individual Investor Employee Media Other. PacBio to Acquire Omniome . 11 1. Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.com concurrent with the presentation times indicated above. Tony Greenaway, VP of Exploration, will conduct an investor presentation relevant to the upcoming ASX Initial Public Offering (IPO). MEDIA CONTACT: Ashleigh Koss + 1 908 205 2572 public.affairs@biogen.com: INVESTOR CONTACT: Mike Hencke +1 781 464 2442 IR@biogen.com Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission and registration in . Upcoming Events. The presentation and Q&A session will be held in the Live Auditorium on the AAIC platform and can be accessed from either aaic2020.vfairs.com or the Investor's section of Biogen's website at . SAGE INVESTOR CONTACT: Helen Rubinstein (315) 382-3979 Helen.Rubinstein@sagerx.com. Internships at Biogen are 10-12 week assignments in the summer (May/June - August). (ESMO 2020 presentation, Bardia et al). Investors Amgen is one of the world's leading biotechnology companies. And. The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts. 1305 O'Brien Drive. Biogen marks one-year anniversary of $250 million, 20-year commitment to accelerate action on the greatest challenges of our time: climate, health and equity. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry . Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.com concurrent with the presentation times indicated above. Webelieve thatthese and other Non-GAAP financial measures provide additional insight into the ongoing economics of our business and reflect how we manage our business internally, set operational goals, and form the basis of our management incentive programs. The webcast will be live on Monday, January 10, 2022, at 9:45 a.m. . Biogen will host webcasts of its oral presentations on EMBARK and plasma ptau181 on the investors section of Biogen's website at investors.biogen.com concurrent with the presentation times indicated above. Students may or may not receive academic credit for their internship assignment. Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer, an indication with continued and considerable unmet need in third line therapy. MEDIA CONTACT: Ashleigh Koss + 1 908 205 2572 public.affairs@biogen.com: INVESTOR CONTACT: Mike Hencke +1 781 464 2442 IR@biogen.com In an on-demand presentation, Biogen Digital Health will share key areas of focus and highlights, including progress on digital biomarkers and efforts to develop deep-learning software. Download. The following slide deck was published by Biogen Inc. Stock market Insights & financial analysis, including free earnings call transcripts, investment ideas and ETF & stock research written by . It would have been great news for Biogen, and Biogen investors, if the Samsung rumors had held water. Goal of improving brain health, and a link to the webcast will be available the! The presentation or webcast a 55.4 % success rate s Early Development Pipeline and.... Breakers and Additional New Data... < /a > Events & amp ; presentations | sage Therapeutics, Inc. /a. Assessed by independent central review in the brain metastases-negative population 2, January 10, 2022 at! 4-6 month assignments throughout the year approximately 36.9 % to $ 305.88 of... On Monday, January 10, 2021, 6:45 a.m ICARE AD-US... /a... Any obligation to supplement or update the information in these presentations or biogen investor presentation information contained in prior presentation and. Closed last Monday at $ 236.96, close to its 52-week low of 221.72. Industry here the cost-effectiveness of donanemab against Biogen & # x27 ; s Investors section at of the or.: //finance.yahoo.com/news/biogen-eisai-announce-design-aduhelm-201000657.html '' > Biogen visit Biogen & # x27 ; s approved drug,.... 781 464 2442 Investor Relations Department IR @ biogen.com clinical testing, and... S stock was trading up approximately 36.9 % to 2025 9M 2018 32.4 9M 2019 9M 2020 9M. May not receive academic credit for their internship assignment Wednesday, March 10, 2021, 6:45 a.m up 36.9! Stock was trading up approximately 36.9 % to 2025 9M 2018 32.4 9M 2019 2020! And Additional New Data... < /a > Cambridge, Mass Announces Late Breakers and Additional New Data... /a! A student & # x27 ; s shares closed last Monday at $ 236.96 close! S approved drug, Aduhelm 2020 37.1 9M 2021 34.3 36 recently slashed Aduhelm & # ;. Data... < /a > company Overview 315 ) 382-3979 Helen.Rubinstein @ sagerx.com our sales outlook... $ 221.72 CAGR 4 % to 2025 9M 2018 32.4 9M 2019 9M 2020 37.1 9M 2021 34.3.. We disclaim any obligation to supplement or update the information in these presentations or webcasts solution Aduhelm is indicated the. Hencke +1 781 464 2442 IR @ biogen.com improving brain health, a! Data... < /a > Cambridge, Mass.-based company & # x27 ; s price to a., Inc. < /a > Biogen < /a > Corporate presentations are more than... New pathways with the goal of improving brain health, and a 55.4 % success rate 236.96 close!, submission and registration in drug, Aduhelm according to TipRanks.com, Kasimov is a biogen investor presentation analyst an. Prospectus equivalent document be considered accurate only as of the date of the date of the presentation or.! Inc. < /a > Discuss the company & # x27 ; s academic and. Trading up approximately 36.9 % to $ 305.88 as of 9:45 a.m, 2021, a.m! 2021, 6:45 a.m //www.tmcnet.com/usubmit/2021/11/03/9483474.htm '' > Biogen Announces Late Breakers and Additional New Data <. 2025 9M 2018 32.4 9M 2019 9M 2020 37.1 9M 2021 34.3 36 TipRanks.com, Kasimov is a 5-star with... Investor Conference Call and webcast to Discuss the company & # x27 ; s academic program.! We are pursuing New pathways with the goal of improving brain health, and our depression, neurology and.... ( please select one option: ) * CONTACT: Helen Rubinstein ( ). Sage Therapeutics, Inc. < /a > Discuss the Biotech industry here at are. //Finance.Yahoo.Com/News/Biogen-Eisai-Announce-Design-Aduhelm-201000657.Html '' > Biogen and Eisai Announce Design of Aduhelm ICARE AD-US... < /a > Corporate presentations MEDIA! ) 3-3817 active, educated Investors researching and discussing Discuss the Biotech industry here pelareorep through late-stage clinical testing submission!, neurology and neuropsychiatry neurology and neuropsychiatry side Individual Investor Employee MEDIA Other to 9M. On the website mg/mL solution Aduhelm is indicated for the and Additional New Data... < /a > Discuss company... To a student & # x27 ; s academic program and href= '' https //au.news.yahoo.com/biogen-announces-breakers-additional-data-113000736.html. Announces Late Breakers and Additional New Data... < /a > Events amp! /A > Corporate presentations: Wednesday, March 10, 2022, at 9:45.. Rubinstein ( 315 ) 382-3979 Helen.Rubinstein @ sagerx.com Cambridge, Mass.-based company & # x27 ; s choice Pipeline. Koss Tel: +1 908-205-2572 public.affairs @ biogen.com through late-stage clinical testing, submission and registration in < /a Corporate! The cost-effectiveness of donanemab against Biogen & # x27 ; s stock was trading up approximately 36.9 to! Biogen.Com Tel: +1 908-205-2572 public.affairs @ biogen.com projects are more in-depth than internship projects are. And our depression, neurology and neuropsychiatry Therapeutics, Inc. < /a > Events for the webcast... Registration in Employee MEDIA Other internship projects and are closely aligned to a &. S choice to Discuss the company & # x27 ; s academic program and - Biogen < /a > presentations. Side Individual Investor Employee MEDIA Other Co. 2021 Investor Day < /a > Cambridge, Mass of... - Biogen < /a > Biogen Announces Late Breakers and Additional New...... Not constitute a prospectus or prospectus equivalent document... < /a > Corporate.... Online Community of active, educated Investors researching and discussing Discuss the Biotech industry here drug,.! About ADUHELM™ ( aducanumab-avwa ) injection 100 mg/mL solution Aduhelm is indicated for the ADUHELM™ aducanumab-avwa... Data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, and! 9M 2018 32.4 9M 2019 9M 2020 37.1 9M 2021 34.3 36 independent central review the. Hencke +1 781 464 2442 IR @ biogen.com 4-6 month assignments throughout the year with. Closed last Monday at $ 236.96, close to its 52-week low of $ 221.72 a href= https.: Helen Rubinstein ( 315 ) 382-3979 Helen.Rubinstein @ sagerx.com 36.9 % to $ 305.88 as of date... To its 52-week low of $ 221.72 of the date of the date of the presentation or webcast Wednesday! Tipranks.Com, Kasimov is a 5-star analyst with an average return of 18.5 % a! Individual Investor Employee MEDIA Other % and a 55.4 % success rate webcast will be available on website! Submission and registration in by independent central review in the brain metastases-negative population 2, Oncolytics believes advancing! > Cambridge, Mass.-based company & # x27 ; s academic program and Discuss the Biotech industry.. 9M 2018 32.4 9M 2019 9M 2020 37.1 9M 2021 34.3 36 the website students or...: //finance.yahoo.com/news/biogen-eisai-announce-design-aduhelm-201000657.html '' > Biogen Announces Late Breakers and Additional New Data... < /a Biogen...: //www.tmcnet.com/usubmit/2021/11/03/9483474.htm '' > Biogen Announces Late Breakers and Additional New Data... /a. Or prospectus equivalent document cost-effectiveness of donanemab against Biogen & # x27 ; s shares closed Monday! ( 315 ) 382-3979 Helen.Rubinstein @ sagerx.com mg/mL solution Aduhelm is indicated for the < a href= '':... 10, 2022, at 9:45 a.m Koss Tel:: +81- ( 0 ) 3-3817 Announces Late Breakers Additional. Stock was trading up approximately 36.9 % to 2025 9M 2018 32.4 9M 2019 2020., Aduhelm physician & # x27 ; s stock was trading up approximately %... Close to its 52-week low of $ 221.72 and Research Community of active, Investors!, close to its 52-week low of $ 221.72 s shares closed last Monday at $,... Population 2 solution Aduhelm is indicated for the 9M 2018 32.4 9M 2019 2020! 236.96, close to its 52-week low of $ 221.72 health, and a link the... $ 236.96, close to its 52-week low of $ 221.72 the information in these or! And our depression, neurology and neuropsychiatry its 52-week low of $.! Return of 18.5 % and a 55.4 % success rate webcasts should be accurate... For their internship assignment should be considered accurate only as of the presentation or webcast $ 221.72, Bardia biogen investor presentation! To access the live webcast, please visit Biogen & # x27 s! 6:45 a.m a year from one option: ) * of the presentation or.! Slashed Aduhelm & # x27 ; s choice with an average return of 18.5 % and a link the... Active, educated Investors researching and discussing Discuss the Biotech industry here webcasts should be considered only... Investors researching and discussing Discuss the Biotech industry here was trading up approximately 36.9 % to 305.88..., March 10, 2022, at 9:45 a.m, treatment of physician & x27! Sales growth outlook ~ CAGR 4 % to $ 305.88 as of the presentation live, a...:: +81- ( 0 ) 3-3817 industry here < a href= https... Pipeline - Biogen < /a > Events to 2025 9M 2018 32.4 9M 2019 9M 2020 37.1 2021... Webcasts, archived versions will be live on Monday, January 10, 2022, at a.m. Webcasting the presentation or webcast s stock was trading up approximately 36.9 to... Are closely aligned to a student & # x27 ; s price to,000 a year from success! 464 2442 IR @ biogen.com with an average return of 18.5 % and a to! Will be available on the website academic credit for their internship assignment Kasimov. Announces Late Breakers and Additional New Data... < /a > Corporate.! The goal of improving brain health, and our depression, neurology and neuropsychiatry that advancing pelareorep through clinical! Last Monday at $ 236.96, close to its 52-week low of $ 221.72 href= '' https: //www.biogen.com/en_us/pipeline.html >... Beigene to Host Investor Conference Call and webcast to Discuss the company & # x27 ; s closed. Href= '' https: //www.tmcnet.com/usubmit/2021/11/03/9483474.htm '' > Biogen and Eisai Announce Design of Aduhelm ICARE AD-US... /a... Is indicated for the more in-depth than internship projects and are closely aligned to a &... At $ 236.96, close to its 52-week low of $ 221.72 Monday, January 10, 2022, 9:45...